Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 10/20 | 0.57 |
| ▸ | PPARG | P37231 | 9/20 | 0.57 |
| ▸ | PPARD | Q03181 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927278 | 0.89 | PPARA (0.64) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL6484104 | 0.88 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL5848718 | 0.88 | CTSK (0.51) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL21153885 | 0.88 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL19710006 | 0.88 | CTSK (0.51) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL15703436 | 0.88 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2118283 | 0.87 | CTSK (0.56) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2118282 | 0.87 | CTSK (0.56) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL7431809 | 0.87 | PPARA (0.56) | PPARAPPARGPPARDCYP1A2CYP2C9 | |
| SCHEMBL2541324 | 0.85 | PPARA (0.57) | PPARAPPARGPPARDCYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433654-A2 | Citrulline and homocitrulline prodrugs of amphetamines and processes for making and using the same | Kempharm, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433655-A2 | Homoarginine-prodrugs of amphetamine | Kempharm, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-8101661-B2 | Polar hydrophilic prodrugs and non-standard amino acid conjugates of amphetamine and other stimulants and processes for making and using the same | KEMPHARM, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110213034-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2011-09-01 | — | — | US | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2010-11-18 | — | — | US | disclosed |
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2010-11-18 | — | — | US | disclosed |
| US-7772222-B2 | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772222-B2 | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SHIRE LLC | 2009-09-24 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-28 | — | — | US | disclosed |
| WO-2008098151-A2 | POLAR HYDROPHILIC PRODRUGS OF AMPHETAMINE AND OTHER STIMULANTS AND PROCESSES FOR MAKING AND USING THE SAME | KEMPHARM, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292337-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | PPARA 774/4885PPARG 873/4885PPARD 1188/4885 |
| US-20090239949-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | PPARA 774/4885PPARG 873/4885PPARD 1188/4885 |
| US-20100292336-A1 | Polar Hydrophilic Prodrugs and Non-Standard Amino Acid Conjugates of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC18A2, SLC6A19, SLC6A2 | PPARA 1313/4885PPARG 1628/4885PPARD 1747/4885 |
| US-20110213034-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A3, SLC6A2, SLC6A15 | PPARA 1930/4885PPARG 1980/4885PPARD 2514/4885 |
| US-20080207757-A1 | Polar Hydrophilic Prodrugs of Amphetamine and Other Stimulants and Processes for Making and Using the Same | SLC6A2, SLC6A3, SLC18A2 | PPARA 774/4885PPARG 873/4885PPARD 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.